Why the study?
Patients with peripheral artery disease tend to have high bleeding risk, but data regarding high bleeding risk in patients after endovascular therapy are limited.
Does the ARC-HBR criteria successfully stratify the risk of bleeding, mortality, and ischemic events in patients with lower extremity PAD undergoing EVT?
Does the ARC-HBR criteria successfully stratify the risk of bleeding, mortality, and ischemic events in patients with lower extremity PAD undergoing EVT?
The ARC-HBR criteria can successfully stratify the 2-year risk of bleeding, mortality, and ischemic events in patients with lower extremity PAD undergoing EVT.
High bleeding risk patients with lower extremity PAD can be at a high risk of bleeding events, mortality, and ischemic events after EVT. The ARC-HBR criteria and its associated scores can successfully stratify HBR patients and assess the bleeding risk in patients with lower extremity PAD who undergo EVT.Clinical ImpactEndovascular therapies (EVTs) for symptomatic lower extremity peripheral artery disease (PAD) are efficient and minimally invasive. However, patients with PAD tend to have high bleeding risk (HBR), and there are limited data regarding the HBR for patients with PAD after EVT. Post EVT, most of the patients with PAD were classified as having HBR using the Academic Research Consortium for HBR (ARC-HBR) criteria and the rate of bleeding events as well as mortality and ischemic events within 2 years increased as the ARC-HBR score increased in this retrospective study of 732 participants. HBR patients with PAD can be at high risk of not only bleeding events but also mortality and ischemic events in the mid-term. The ARC-HBR criteria and its associated scores can successfully stratify HBR patients and assess the bleeding risk in patients with PAD who underwent EVT.
No takes yet. Share an insight, caveat, or question.
Yoshioka et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: